Guidance for Topical Treatment Use Based on BSA in AD
Experts in dermatology share general guidance for use of topicals, switching from topical to systemic treatment, and when combination therapy is an option for patients with atopic dermatitis.
Read More
Challenges and Advantages in Use and Access to Biologics for Atopic Dermatitis
Drs Raj Chovatiya, George Han, and Vivian Shi review the current challenges and opportunities surrounding the utilization and availability of biologic therapies in atopic dermatitis.
Considerations for Biologic Treatments in Pediatric Patients with Atopic Dermatitis
Expert dermatologists highlight the burden of atopic dermatitis in young children and examine the clinical data for dupilumab, a biologic treatment for this age group.
Therapy Individualization for Atopic Dermatitis
The expert panel discusses the heterogeneity of atopic dermatitis manifestation and therapy decisions for individual patients.
Treatment Landscape in Atopic Dermatitis for Different Age Groups
Dr Vivian Shi provides an overview of treatment options for atopic dermatitis patients in different age groups.
Monitoring AD Treatments in Various Age Groups
Omar Noor, MD, and Adelaide A. Hebert, MD, discuss monitoring requirements for various classes of treatments in atopic dermatitis, including topical vs systemic.
Treatment Options for Patients With Moderate Disease Over 10%-20% BSA
Peter A. Lio, MD, reviews treatment options for patients with moderate AD.
Treatment Goals in AD
Matthew Zirwas, MD, shares goals of therapy for a patient with AD.
Implications of Boxed Warnings of Topical JAK inhibitors
Expert dermatologists address the clinical implications of boxed warnings of topical treatments in AD.
Time to Response in AD
Matthew Zirwas, MD, and Omar Noor, MD, comment on their own experience of time to response with topical and systemic treatments of AD.
Durability of Response to Treatment in AD
Peter A. Lio, MD, discusses the durability of topical treatments in AD, including steroids, calcineurin inhibitors, and JAK inhibitors.
Efficacy Data for Topical Treatment of AD
Experts discuss long-term efficacy data for topical medications for the treatment of AD.
Patient With Limited Disease Activity in AD
Matthew Zirwas, MD, and Omar Noor, MD, review a patient scenario where AD disease activity is limited but in difficult to treat locations.
AD Treatment Options for Patients Moving Away from Long-Term Steroids
Peter A. Lio, MD, shares his approach to presenting treatment alternatives to patients who want to stop using long-term steroids for treatment of AD.
Challenges Faced by Non-Dermatologists When Using Steroids
Adelaide A. Hebert, MD, comments on the need for nondermatologist education on the basics of skin disease care.
Durability of Topical Steroid Use in AD
Expert dermatologists discuss the durability of long-term use of topical steroids for treatment of atopic dermatitis.
Patient on Long-Term Steroidal Use in AD
Adelaide A. Hebert, MD, reviews the use of long-term steroids for treatment of atopic dermatitis.
Advice for Managing Patients With PN
Shawn Kwatra, MD, and Sarina B. Elmariah, MD, PhD, share final pearls of wisdom for other physicians taking care of patients with prurigo nodularis (PN).
Unmet Needs in PN
Experts in dermatology discuss unmet needs in prurigo nodularis (PN) and the importance of addressing those needs for disease management.
Emerging Treatments for PN
Drs Raj Chovatiya, Shawn Kwatra, and Sarina B. Elmariah review exciting new therapies in the treatment landscape of PN.
Factors Guiding Treatment Selection in AD
Experts in dermatology discuss which disease characteristics play the biggest role in influencing treatment choice or change of treatment from the perspective of a patient with atopic dermatitis.
Treatment Options and Targets in Atopic Dermatitis (AD)
A panel of expert dermatologists comments on newly approved and traditional treatment options, addressing how they target inflammation and the pathophysiology of atopic dermatitis (AD).
Conducting Additional Research to Improve PN Management
Experts in dermatology share thoughts on the need for additional investigative research of prurigo nodularis in order to better treat patients.
Challenges in Using Dupilumab in PN
Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, discuss potential challenges to the adoption of dupilumab in the treatment of PN.
Patient Selection for Dupilumab in PN
Experts in dermatology discuss ideal candidates for dupilumab.
Phase 3 Clinical Trials With Dupilumab in PN
Drs Raj Chovatiya, Shawn Kwatra, and Sarina B. Elmariah review PRIME and PRIME 2 phase 3 studies of dupilumab for treatment of PN.
Role of Dupilumab for Treatment of PN
Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD, discuss a newly approved drug, dupilumab, for the treatment of PN.
Challenges of Topical Medication Use in PN
Raj Chovatiya, MD, PhD, reviews the limitations of topical treatments when managing PN.
Less Commonly Used Medications in PN
Sarina B. Elmariah, MD, PhD, talks about less commonly used treatments for patients with prurigo nodularis (PN).
Treatment Options for PN
Raj Chovatiya, MD, PhD; Shawn Kwatra, MD; and Sarina B. Elmariah, MD, PhD; provide an overview of therapies currently available for treating PN.